Patients with resistant hypertension (RH) are known to have higher prevalence of target organ damage 1, 2 and to be more likely to experience a cardiovascular (CV) event 3 than patients whose blood pressure (BP) is under control. In patients with confirmed RH, determinants that have been associated most often with CV risk are ambulatory BPs rather than office BPs 4,5 and subclinical organ alterations, such as left ventricular hypertrophy (LVH). 6 In terms of renal parameters, both reduced glomerular filtration rate (GFR) 7, 8 and albuminuria 9 have been shown to have an independent predictive value in regard to cardiovascular outcomes within the community [10] [11] [12] [13] [14] and in hypertensive [15] [16] [17] patients. However, their prognostic usefulness in RH patients has not been evaluated frequently. To our knowledge, there has been only one study to suggest an association between both reduced renal function and albuminuria at baseline, as well as their interaction and subsequent development of CV events and mortality. 18, 19 However, in regard to changes in albuminuria over time, no definite association was found. 19 We hypothesized that renal function and urinary albumin excretion may have a true, independent prognostic value for CV outcomes in RH patients, not only at baseline but also at follow-up. Accordingly, we assessed the predictive value of these renal parameters in a cohort of patients with RH who were followed up for a mean of 6 years.
METHODS

Study patients
In this long-term observational study, 143 patients were consecutively enrolled between April 2004 and January 2006 from 4 hypertension units at university hospitals in Barcelona, Spain. These patients fulfilled the criteria to diagnose RH (office BP ≥ 140/90 mm Hg despite treatment with 3 or more antihypertensive drugs, including a diuretic, all at the maximum tolerated doses) and provided written informed consent. The local institutional ethic committees approved the study protocol. The investigation conformed with the principles outlined in the Declaration of Helsinki. Baseline protocol and diagnostic definitions have been detailed elsewhere. [20] [21] [22] Briefly, all patients were submitted to a standard protocol based on records of clinical characteristics, basic laboratory evaluation including determination of urine albumin/creatinine, 2D echocardiography, and 24-hour ambulatory BP monitoring (24-hour ABPM). In addition, patients had to meet the following criteria: secondary hypertension ruled out, estimated-GFR (eGFR) ≥ 30 ml/ min/1.73m 2 , good treatment adherence assessed by standard validated questionnaire administered by a trained nurse, lack of use of long-term corticosteroid or nonsteroidal antiinflammatory therapies, and free of cardiovascular events 6 months prior to their inclusion.
Previous history of CV disease (CVD) was considered in cases of confirmed stroke, acute myocardial infarction, or unstable angina; hospitalization due to heart failure; or ischemic peripheral vascular disease that required amputation or revascularization. Diabetes mellitus was diagnosed using medical history if antidiabetic treatment had been implemented or when the patient had a minimum of 2 fasting plasma glucose determinations > 7.0 mmol/L. Dyslipidemia was considered if patients were being treated with lipid-lowering drugs, total cholesterol was > 5.0 mmol/L, low-density lipoprotein cholesterol was > 3.0 mmol/L, high-density lipoprotein cholesterol was < 1.0 mmol/L (men) or < 1.2 mmol/L (women), or triglycerides were >1.7 mmol/L. Ten patients (7%) were lost from follow-up because of a change of address. Consequently, no clinical records were available beyond baseline, and they were excluded from the study. At least 1 second laboratory evaluation and office BP measurement at follow-up were available for the remaining 133 patients, and these entered the study.
Measurement of office BP and 24-hour ABPM
Office BP measurement. Office BP was measured in accordance with current guidelines. Subjects rested for 5 minutes in the sitting position. BP was measured 3 times at 2-minute intervals using a validated oscillometric semiautomatic device (Omron 705IT, Kyoto, Japan) with appropriate-sized cuff. The average of these BP records was the definitive office BP value considered in this study. Office BP measurement was obtained in this way both at baseline and at all follow-up visits.
24-hour ABPM. All patients underwent a 24-hour ABPM with a validated device (Spacelabs-90207, Issaquah, WA) upon entry to the study. Ambulatory BP recordings were taken on a weekday, starting between 8 am to 10 am, at 20-minute intervals throughout both the awake (from 10 to 20 hours) and asleep (from 0 to 6 hours) periods. A 24-hour ABPM of good technical quality (percentage of valid readings > 80%) was a mandatory requisite to enter the study; otherwise, a second 24-hour ABPM was carried out. Although RH is defined by office BP criteria, we confirmed true RH when 24-hour BP was ≥ 130 and/or 80 mm Hg.
Laboratory renal parameters
Urinary albumin excretion. Urinary albumin excretion (measured by turbidimetry; lower detection limit: 0.3 mg/ dl; intraassay and interassay variation coefficients: 1.3% and 4.3%, respectively) was determined upon entry to the study and at follow-up and measured as the average of urinary albumin/creatinine ratio (UACR) from 3 first-morning-void urine samples obtained on separate days. Microalbuminuria was defined as a UACR ≥ 30 mg/g. 23 Serum creatinine and eGFR. Serum creatinine (SCr) was measured by an enzymatic modified Jaffé reaction (CREA; Roche Diagnostics), consistent with the current recommendations for standardizing SCr measurement 24 (intraassay coefficient of variation: 2.3%). The eGFR was calculated using the Chronic Kidney Disease-Epidemiology Collaborative equation 25 
Echocardiography
Echocardiographic examinations were performed in accordance with current guidelines, and left ventricular mass was calculated following the American Society of Echocardiography recommendations, 26 being indexed to body surface area to give left ventricular mass index. The diagnosis of LVH was considered if left ventricular mass index was > 125 g/m 2 (men) and > 110 g/m 2 (women). 27 
Follow-up and endpoints
All 133 patients included in the study underwent another complete laboratory analysis and office BP measurements in accordance with the above-described protocol approximately 6 years after entering the study (median [p25; p75]: 73 months [52.5; 82.5]). The primary endpoint was a composite of the first occurrence of a nonfatal CV event (myocardial infarction, stroke, hospitalization due to new-onset heart failure, any coronary revascularization, or a lower limb revascularization procedure or amputation) or CV death. The occurrence of CV events (fatal and nonfatal) was ascertained from medical records or death certificates.
Statistical analyses
Continuous variables are summarized by mean ± SD if normally distributed or by median [p25; p75] otherwise. Categorical variables are described as frequencies and percentages for each category. Bivariate comparisons between patients with and without CV outcomes were performed by unpaired t tests with continuous data, by Mann-Whitney test with asymmetrically distributed data, and by χ 2 test with categorical data. An analysis of variance with the repeated measures design was then performed to assess the possible association of renal parameters at baseline and at follow-up with the composite CV endpoint. Analyses were performed before and after adjustment for age and office systolic BP, both at baseline and at follow-up, and for previous CV disease. To evaluate the association of UACR with the primary composite endpoint, analyses were also adjusted for eGFR both at baseline and follow-up in addition to the aforementioned confounders. Because of skewed distribution, UACR was tested after log-transformation.
RESULTS
A total of 133 patients with a clinical diagnosis of RH were analyzed. Mean age ± SD was 61 ± 9 years, and 59% were males. Baseline median [p25; p75] UACR was 18.2 mg/g [7; 73.3]. Overall prevalence of microalbuminuria was 42% and that of impaired renal function (eGFR < 60 ml/min/1.73m 2 ) was 29%. During a median follow-up of 73 months, 22 patients (16.5%) reached the primary endpoint, and 26 fatal and nonfatal CV events occurred among them (3 cardiovascular deaths; 7 acute coronary events, either myocardial infarction or coronary revascularization; 9 strokes; 4 hospitalizations due to new-onset heart failure; and 3 cases in which a lower limb revascularization procedure or amputation was required). Median time to the occurrence of the first CV event was 45 months [24; 62] . In addition, there were 9 noncardiovascular deaths. Table 1 outlines the baseline characteristics of patients, with comparisons between those who developed the primary CV composite endpoint at follow-up and those who did not, according to bivariate analyses. Patients who developed the primary endpoint were older and had a higher prevalence of previous CVD. Patients who reached the primary CV composite endpoint had worse renal function, based on SCr and eGFR values. Prevalence of microalbuminuria as well as UACR levels were not significantly different between both groups at baseline. Otherwise, left ventricular mass index and LVH prevalence were quite similar in patients with and without CVD development at follow-up. Regarding antihypertensive treatment, all patients were taking a diuretic, and the percentage of patients taking a renin-angiotensin system blocker (RAS blocker), a calcium channel blocker, a beta-blocker, an alpha-blocker, or a central vasodilator was 96%, 77%, 60%, 38%, and 6%, respectively. Table 2 shows the comparison of BP data between groups. At baseline, there were no significant differences in either office or 24-hour ambulatory-monitored BP parameters, although there was a trend of lower diastolic BPs in patients who developed CVD during follow-up. For office BP at follow-up, no differences were observed for systolic BP, whereas diastolic BP was significantly lower (P = 0.045) in the group of patients who suffered a CV event.
An analysis of variance with the repeated measures design was performed to assess whether any of the renal parameters at baseline and follow-up were associated with the composite CV endpoint. UACR elevation at follow-up (66 vs. 17 mg/g; P = 0.045) was significantly associated with the development of CV events, after adjustments for age, previous CVD, and both office systolic BP and eGFR measured at baseline and at follow-up (Table 3 ). Renal function, as measured by SCr levels and eGFR, did not significantly change at follow-up in patients with or without CV events. Although, as previously mentioned, the former group had a worse baseline renal function, differences did not remain significant after adjustments for possible confounders. Even though the proportion of true RH in patients with or without CV events did not significantly differ, we wanted to confirm these results by considering only patients with true RH (73% of this cohort). Consequently, we performed sensitivity analyses in this subgroup (Supplementary Table A ) and showed the same findings.
When exploring the relationships between albuminuria as a categorized variable and CV events, we observed that percentages of patients with microalbuminuria at baseline were quite similar in those developing and those not developing the primary composite CV endpoint, 45% and 41%, respectively (P = 0.813). However, the proportion of patients with microalbuminuria at follow-up differed significantly between both groups: 67% and 28%, respectively (P = 0.002). To further analyze the association between microalbuminuria evolution and CV outcomes, we established 4 groups of patients depending on UACR changes (Table 4) . As compared with patients who did not experience CVD, more patients who had new-onset CVD developed microalbuminuria at follow-up (28% vs. 6%) or had persistent microalbuminuria (39% vs. 21%), whereas the percentage of patients with microalbuminuria regression was lower in the group who had new-onset CVD (11% vs. 19%); this also occurred in patients with persistent normoalbuminuria (22% vs. 53%). The overall P was 0.005 for the comparisons of the percentages of the 4 groups of evolution of albuminuria among patients with new-onset CVD at follow-up and patients without.
DISCUSSION
Among well-characterized patients with RH, 16 .5% experienced at least 1 CV event over a median follow-up of 73 months. In addition to well-known prognostic factors, such as age and a previous history of CVD, the main prognostic factor of the primary CV composite endpoint was maintenance of or development of high urinary albumin excretion. The presence of microalbuminuria at followup was the only valid variable for predicting CV outcome.
Neither the albuminuria at baseline nor the renal function, as assessed by SCr or eGFR, showed an independent predictive value after adjusting for confounders.
To date, there has been only 1 report on the prognostic effect of baseline albuminuria in patients with RH. 19 Researchers have provided interesting information on the impact of serial changes in renal parameters on CV outcomes in populations other than those with RH. In hypertensive patients with type 2 diabetes, a reduction of albuminuria was associated with a lower incidence of CV events 28, 29 and mortality, 30 and the same results were obtained in those with hypertension and LVH. 31 Similarly, changes in albuminuria predicted mortality and CV and renal outcomes in patients with vascular disease or diabetes independently of baseline albuminuria. 32 To our knowledge, only one study has reported on the predictive value of serial changes in albuminuria in patients with RH. 19 However, the authors did not find a significant association between changes in microalbuminuria and CVD development. In our study we demonstrate for the first time that regardless of the baseline albuminuria in patients with resistant and, consequently uncontrolled, hypertension, the determining factor for their CV prognosis is the albuminuria level reached at follow-up or, i.e., the inability to regress it or to prevent its development. This finding is crucial because, given that albuminuria is frequently elevated in patients with RH, 2,20,21 the superiority of this value at follow-up as compared to its value at the initial patient evaluation indicates that albuminuria should theoretically be considered a required therapeutic target. The second important finding is that changes in albuminuria are not only an independent predictor of CV morbidity and mortality in these patients, but the prognostic value of these changes is higher than that offered by the more common renal parameters of SCr level and eGFR. In patients with type 2 diabetes and hypertension, 33 microalbuminuria was shown to be an important predictor of CV outcome independently of eGFR. In RH patients, others have assessed the prognostic value of renal parameters. Daugherty 3 recently showed that RH patients had an increased CV risk as compared to patients with hypertension with controlled BP, largely caused by development of chronic kidney disease.
However, albuminuria was not evaluated in this study. In our cohort of RH patients with long-term follow-up, we examined SCr level, eGFR, and albuminuria, both at baseline and at follow-up. Although baseline renal function was associated with CV outcome in unadjusted analyses, the significance was lost after adjustments for age, previous CVD history, and BP. Remarkably, follow-up albuminuria, but not baseline albuminuria, determined either as a continuous variable or as a dichotomized variable, independently predicted CV outcomes. This result differs from that reported by Salles et al 19 who found that RH patients who regressed microalbuminuria had a nonsignificant 27% lower risk of CV morbidity/mortality than those with persistent microalbuminuria. In addition, those who developed microalbuminuria had a nonsignificant (65%) higher risk of having a CV event as compared to those who remained without microalbuminuria. In these patients, albuminuria was determined at the second year of follow-up; in our study, confirmatory results were found when albuminuria was evaluated at a mean follow-up of approximately 6 years. The finding of this positive association could be explained by the longer follow-up period of our cohort. Another methodological difference between the studies is that measurement of P values refer to the comparisons between the associations of renal parameters with the composite cardiovascular endpoint, both at baseline and during follow-up.
Abbreviations: CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; SCr, serum creatinine; UACR, urinary albumin/ creatinine ratio.
a Data are given as median [p25; p75]. Remaining data are given as mean ± SD or percentages. b Adjusted for age, office systolic blood pressure both at baseline and during follow-up, and previous CVD c Adjusted for the aforementioned confounders plus eGFR both at baseline and at follow-up. UACR tested after log-transformation. Overall P = 0.005. This P value refers to the comparisons of the percentages of the 4 groups of evolution of albuminuria among patients who developed new-onset CVD at follow-up and patients who did not.
Abbreviations: b, baseline; CVD, cardiovascular disease; f-u, follow-up; N, normoalbuminuria; MA, microalbuminuria. urinary albumin excretion was obtained from a single urine sample in the cohort reported by Salles et al, 19 whereas we averaged albuminuria from 3 samples. Moreover, regarding our own results, this is the first time in RH patients where changes in albuminuria over time are shown to be independently associated with CV risk, agreeing with what has been reported in other populations, namely, those with hypertension and type 2 diabetes, vascular disease, [28] [29] [30] 32 or LVH. 31 It is generally accepted that the extent of reduction in albuminuria is greater by blocking the RAS rather than with other classes of antihypertensive drugs. Even though RAS blockers were given in these aforementioned trials, [28] [29] [30] [31] [32] the protective effect of albuminuria reduction on CV events and mortality was independent of specific antihypertensive medications. Anyway, this protective effect of albuminuria was not initially intended but was a post-hoc analysis in most of them. In our study, most patients, those with or without new-onset CVD, received RAS blockers as part of their therapeutic schedule (Table 1) . Based on these data, we cannot deduce a role for RAS blockers in the association of albuminuria with CVD.
Our study reinforces the key role of albuminuria in the monitoring of RH patients to assess their overall CV risk, even though we cannot infer from these data whether persistent microalbuminuria reflects a more severe inflammatory state or a therapeutic failure.
There are some limitations to our study. First, because it was not an interventional study, we could not infer that other therapeutic measures capable of modifying albuminuria, such as a more complete blocking of the RAS or the use of some other drugs, could improve the CV prognosis in these patients. Second, the study was conducted in a medium-sized RH cohort, which makes it unfeasible to determine certain parameters, such as the specific threshold of albuminuria at follow-up that defines the population at higher risk. Finally, 7% of the initially enrolled patients were lost to follow-up due to nonmedical reasons. However, in terms of its strengths, our results are in the line with what has been observed in CV risk subgroups other than RH patients. [28] [29] [30] [31] [32] Moreover, the detailed evaluation of this cohort of patients with determination of albuminuria in more than a unique urine spot, and baseline BP measurement both at office and by 24-hour ABPM, allowed us to confirm the great value of albuminuria either maintained or developing over time to assess CV risk in RH patients, independently of renal function, BP levels, or other CV risk factors and other markers of subclinical organ damage, such as LVH. In fact, although both LVH and microalbuminuria are wellknown risk markers for CVD, their pathogenic pathways may be different, as suggested in the Losartan Intervention for Endpoint Reduction in Hypertension study, 16 where fatal and nonfatal CV events increased across deciles of microalbuminuria in patients with LVH. Finally, the sensitivity analyses performed in the subgroup of patients with true RH strengthens the value of these results.
In conclusion, this study confirms that the determination of albuminuria, a noninvasive and cost-effective tool, is an excellent marker of long-term CV risk in patients with RH, beyond its value in the initial evaluation of the patient. Therefore, albuminuria confirms to be a mandatory subclinical target organ damage marker when following up on a RH patient to better assess the overall cardiovascular risk. This may imply an increase in the overall treatment of RH patients. However, intervention studies aimed at reducing albuminuria should be developed to determine its effects on CV outcomes over time.
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